{"id":"NCT01146652","sponsor":"Sanofi","briefTitle":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","officialTitle":"A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-21","primaryCompletion":"2020-12-31","completion":"2020-12-31","firstPosted":"2010-06-17","resultsPosted":"2022-01-24","lastUpdate":"2022-03-28"},"enrollment":2023,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"SAR153191 (REGN88)","otherNames":[]}],"arms":[{"label":"Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)","type":"EXPERIMENTAL"},{"label":"Sarilumab monotherapy","type":"EXPERIMENTAL"}],"summary":"Main Study:\n\nPrimary Objective:\n\nAssess the long term safety of sarilumab in participants with rheumatoid arthritis (RA).\n\nSecondary Objective:\n\nAssess the long term efficacy of sarilumab in participants with RA.\n\nSub-Study:\n\nThis phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)","effectByArm":[{"arm":"Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)","deltaMin":1760,"sd":null},{"arm":"Sarilumab Monotherapy","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":335,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Ecuador","Estonia","Finland","Germany","Greece","Guatemala","Hungary","Israel","Italy","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Peru","Philippines","Poland","Portugal","Romania","Russia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["36727470","36413080","33871596","33164349","31452928"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":617,"n":1910},"commonTop":["Neutropenia","Accidental Overdose","Upper Respiratory Tract Infection","Urinary Tract Infection","Nasopharyngitis"]}}